HIVPhase 3REPRIEVENCT02344290
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
A Phase 3 study testing Pitavastatin in people with HIV and Cardiovascular Diseases, run by National Institute of Allergy and Infectious Diseases (NIAID) at 137 sites in 13 countries.
Trial summary
People with HIV are at risk for cardiovascular disease (CVD). This study evaluated the use of pitavastatin to reduce the risk of CVD in adults with HIV on antiretroviral therapy (ART). Read more about this study
- Who is it for?
- Ages 40 to 75 years
- Conditions the study is for
- HIV, Cardiovascular Diseases
- What is being tested?
- Pitavastatin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 7,769 participants
- Where
- 137 sitesin 13 countries
- Study dates
- 26 Mar 2015to 21 Aug 2023
- Phase
- Phase 3
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Individual with HIV-1
- Combination antiretroviral therapy (ART) for at least 180 days prior to study entry
- CD4+ cell count greater than 100 cells/mm^3
- Acceptable screening laboratories including:
- Fasting low-density lipoprotein (LDL) cholesterol as follows:
- If ASCVD risk score was less than 7.5%, LDL cholesterol must have been less than 190 mg/dL.
Show all 15Show fewer
- If ASCVD risk score was greater than or equal to 7.5% and less than or equal to 10%, LDL must have been less than 160 mg/dL.
- If ASCVD risk score was greater than 10% and less than or equal to 15%, LDL must have been less than 130 mg/dL.
- Participants with LDL less than 70 mg/dL were eligible regardless of the 10-year ASCVD risk score, in line with the ACC/AHA 2013 Prevention Guidelines.
- Fasting triglycerides less than 500 mg/dL
- Hemoglobin greater than or equal to 8 g/dL for female participants and greater than or equal to 9 g/dL for male participants
- Glomerular filtration rate (GFR) greater than or equal to 60 mL/min/1.73m^2 or creatinine clearance (CrCl) greater than or equal to 60 mL/min
- Alanine aminotransferase (ALT) less than or equal to 2.5 x the upper limit of normal (ULN)
- For persons with known chronic active hepatitis B or C, calculated fibrosis 4 score (FIB-4) must have been less than or equal to 3.25
- Ability and willingness of participant or legal representative to provide written informed consent
Who cannot join
- Clinical ASCVD, as defined by 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines, including a previous diagnosis of any of the following:
- Acute myocardial infarction (AMI)
- Acute coronary syndromes
- Stable or unstable angina
- Coronary or other arterial revascularization
- Stroke
Show all 23Show fewer
- Transient ischemic attack (TIA)
- Peripheral arterial disease presumed to be of atherosclerotic origin
- Current diabetes mellitus with LDL greater than or equal to 70 mg/dL
- 10-year ASCVD risk score estimated by Pooled Cohort Equations greater than 15%
- Active cancer within 12 months prior to study entry, except successfully treated non-melanomatous skin cancer and Kaposi sarcoma without visceral organ involvement
- Known decompensated cirrhosis
- History of myositis or myopathy with active disease in the 180 days prior to study entry
- Known untreated symptomatic thyroid disease
- History of allergy or severe adverse reaction to statins
- Use of specific immunosuppressants or immunomodulatory agents including but not limited to tacrolimus, sirolimus, rapamycin, mycophenolate, cyclosporine, tumor necrosis factor (TNF)-alpha blockers or antagonists, azathioprine, interferon, growth factors, or intravenous immunoglobulin (IVIG) in the 30 days prior to study entry.
- Current use of erythromycin, colchicine, or rifampin
- Use of any statin drugs, gemfibrozil, or PCSK9 inhibitors in the 90 days prior to study entry
- Current use of an investigational new drug that would be contraindicated
- Serious illness or trauma requiring systemic treatment or hospitalization in the 30 days prior to study entry
- Current pregnancy or breastfeeding
- Alcohol or drug use that, in the opinion of the site investigator, would interfere with completion of study procedures
- Other medical, psychiatric, or psychological condition that, in the opinion of the site investigator, would interfere with completion of study procedures and or adherence to study drug
Trial locations and contacts
137 sites in 13 countries.
137 sites in 13 countries
United States91 sites
The Ponce de Leon Center CRS
Atlanta, Georgia, 30308-2012
Augusta University Research Institute, Inc. CRS
Augusta, Georgia, 30912
University of Colorado Hospital CRS*
Aurora, Colorado, 80045
Johns Hopkins University CRS*
Baltimore, Maryland, 21205
Alabama CRS*
Birmingham, Alabama, 35294
Tufts Medical Center CRS
Boston, Massachusetts, 02111
Massachusetts General Hospital CRS (MGH CRS)*
Boston, Massachusetts, 02114
Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS*
Boston, Massachusetts, 02115
Boston Medical Center CRS
Boston, Massachusetts, 02118
Cooper Univ. Hosp. CRS
Camden, New Jersey, 08103
Chapel Hill CRS*
Chapel Hill, North Carolina, 27599
Medical University of South Carolina: Division of Infectious Diseases CRS
Charleston, South Carolina, 29425
Northwestern University CRS*
Chicago, Illinois, 60611
Rush University CRS*
Chicago, Illinois, 60612
UIC Project WISH CRS
Chicago, Illinois, 60612
Cincinnati Clinical Research Site*
Cincinnati, Ohio, 45219
Case Clinical Research Site*
Cleveland, Ohio, 44106
Prisma Health CRS
Columbia, South Carolina, 29209
Ohio State University CRS*
Columbus, Ohio, 43210
Trinity Health and Wellness Center CRS
Dallas, Texas, 75208
Dallas VA Medical Center CRS
Dallas, Texas, 75216
UT Southwestern HIV/ID Clinical Trials Unit CRS
Dallas, Texas, 75235-9173
Denver Public Health CRS
Denver, Colorado, 80204
Henry Ford Hosp. CRS
Detroit, Michigan, 48202
Duke University Medical Center CRS
Durham, North Carolina, 27710
Inova Heart and Vascular Institute CRS
Falls Church, Virginia, 22042
Malcom Randall VA Medical Center CRS
Gainesville, Florida, 32610
Greensboro CRS*
Greensboro, North Carolina, 27401
Houston AIDS Research Team CRS*
Houston, Texas, 77030
Michael E. DeBakey VAMC REPRIEVE CRS
Houston, Texas, 77030
Indiana University Infectious Diseases Research CRS
Indianapolis, Indiana, 46202
Department of Internal Medicine, University of Iowa Hospitals & Clinics CRS
Iowa City, Iowa, 52242
University of Mississippi Medical Center CRS
Jackson, Mississippi, 39213
Bluegrass Care Clinic/University of Kentucky Research Foundation CRS
Lexington, Kentucky, 40536
University of Southern California CRS*
Los Angeles, California, 90033-1079
UCLA CARE Center CRS*
Los Angeles, California, 90035
Mills Clinical Research CRS
Los Angeles, California, 90069
VA West Los Angeles Medical Center CRS
Los Angeles, California, 90073
Los Angeles LGBT Center CRS
Los Angeles, California, 90232
550 Clinic -University of Louisville CRS
Louisville, Kentucky, 40202
AHF-The Kinder Medical Group CRS
Miami, Florida, 33133
The University of Miami AIDS Clinical Research Unit (ACRU) CRS
Miami, Florida, 33136
University of Miami Infectious Disease Research Unit at Jackson Memorial Hospital CRS
Miami, Florida, 33136
AHF - South Beach CRS
Miami, Florida, 33140
Medical College of Wisconsin, Inc. CRS
Milwaukee, Wisconsin, 53226
Abbott Northwestern Hospital CRS
Minneapolis, Minnesota, 55407
Vanderbilt Therapeutics (VT) CRS*
Nashville, Tennessee, 37204
Yale University CRS
New Haven, Connecticut, 06510
Tulane - Louisiana Community AIDS Research Program (T-LaCARP) CRS
New Orleans, Louisiana, 70112
Mount Sinai Beth Israel CRS*
New York, New York, 10003
VA New York Harbor Healthcare System (NYHHS), NY Campus CRS
New York, New York, 10010
Weill Cornell Chelsea CRS*
New York, New York, 10010
Mount Sinai Downtown CRS*
New York, New York, 10011
Mount Sinai West Samuels CRS*
New York, New York, 10019
Mount Sinai St. Luke's Morningside CRS*
New York, New York, 10025
Infectious Disease Clinical and Translational Research Center (CTRC) CRS
New York, New York, 10029
Columbia P&S CRS*
New York, New York, 10032-3732
Weill Cornell Uptown CRS*
New York, New York, 10065
New Jersey Medical School Clinical Research Center CRS*
Newark, New Jersey, 07103
Specialty Care Center CRS
Omaha, Nebraska, 68106
Orlando Immunology Center CRS
Orlando, Florida, 32803
Eisenhower Health Center at Rimrock CRS
Palm Springs, California, 92264
Stanford AIDS Clinical Trials Unit CRS
Palo Alto, California, 94304-5350
Division of Infectious Diseases Clinical Research Center- Drexel University CRS
Philadelphia, Pennsylvania, 19102
Penn Therapeutics, CRS*
Philadelphia, Pennsylvania, 19104
Center of Translational AIDS Research, Lewis Katz School of Medicine at Temple University CRS
Philadelphia, Pennsylvania, 19140
Positive Health Clinic CRS
Pittsburgh, Pennsylvania, 15212
University of Pittsburgh CRS*
Pittsburgh, Pennsylvania, 15213
The Miriam Hospital Clinical Research Site (TMH CRS) CRS*
Providence, Rhode Island, 02906
Virginia Commonwealth University CRS
Richmond, Virginia, 23298
University of Rochester Adult HIV Therapeutic Strategies Network CRS*
Rochester, New York, 14642
UCSD Antiviral Research Center CRS*
San Diego, California, 92103
Ucsf Hiv/Aids Crs*
San Francisco, California, 94110
Community AIDS Network/Comprehensive Care Clinic CRS
Sarasota, Florida, 34237
University of Washington AIDS CRS*
Seattle, Washington, 98104-9929
St. John Newland Medical Associates CRS
Southfield, Michigan, 48075
Baystate Infectious Diseases Clinical Research CRS
Springfield, Massachusetts, 01199
Washington University Therapeutics (WT) CRS*
St Louis, Missouri, 63110-1010
Florida Department of Health - Hillsborough County
Tampa, Florida, 33602
James J Peters VA Medical Center CRS
The Bronx, New York, 10468
University of Toledo Medical Center CRS
Toledo, Ohio, 43614
Harbor-UCLA CRS*
Torrance, California, 90502
University of Arizona CRS
Tucson, Arizona, 85724
Oklahoma State University Center for Health Sciences CRS
Tulsa, Oklahoma, 74127
AIDS Research and Treatment Center of the Treasure Coast CRS
Vero Beach, Florida, 32960
Whitman-Walker Health CRS
Washington D.C., District of Columbia, 20005
Georgetown University CRS (GU CRS)
Washington D.C., District of Columbia, 20007
Capital Medical Associates, PC CRS
Washington D.C., District of Columbia, 20036
Infectious Diseases Clinic, Washington DC Veterans Affairs Medical Center CRS
Washington D.C., District of Columbia, 20422
VA Connecticut Healthcare System CRS
West Haven, Connecticut, 06516
Wake Forest Baptist Medical Center CRS
Winston-Salem, North Carolina, 27157
Spain13 sites
Hospital General Universitario de Alicante
Alicante, 03010
Hospital Germans Trias i Pujol
Badalona, 080916
Hospital Universitario Valle d'Hebron
Barcelona, 08003
Hospital Clinic de Barcelona
Barcelona, 08036
Hospital Universitario de Bellvitge
Barcelona, 08907
Hospital Universitario de Basurto de Basurto
Bilbao, 48013
Hospital General Universitario De Elche
Elche, 03203
Hospital Gregorio Universitario Maranon
Madrid, 28007
Hospital Universitario Ramon y Cajal
Madrid, 28034
Hospital Universitario Clinico San Carlos
Madrid, 28040
Hospital Universitario 12 de Octubre
Madrid, 28041
Hospital Universitario La Paz
Madrid, 28046
Hospital Universitario Virgen de la Victoria
Málaga, 29010
Brazil10 sites
School of Medicine, Federal University of Minas Gerais CRS
Belo Horizonte, Minas Gerais, 30130-100
Tropical Medicine Foundation Dr. Heitor Vieira Dourado CRS
Manaus, Amazonas, 69040000
HGNI HIV Family Care Clinic - HHFCC CRS
Nova Iguaçu, Rio de Janeiro, 26030-380
Hospital Nossa Senhora da Conceicao CRS
Porto Alegre, Rio Grande do Sul, 91350-200
Projeto Praça Onze Pesquisa em Saúde CRS
Rio de Janeiro, 20020-000
Hospital Federal dos Servidores do Estado CRS
Rio de Janeiro, 20221-903
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS
Rio de Janeiro, 21040-360
Centro de Referencia e Treinamento DST/AIDS CRS
São Paulo, São Paulo, 04121-000
Instituto de Infectologia Emilio Ribas CRS
São Paulo, 01246-900
Centro de Pesquisas Clínicas IC-HCFMUSP CRS
São Paulo, 05403-010
Canada6 sites
Hamilton Health Sciences - Special Immunology Services Clinic CRS
Hamilton, Ontario, L8S 1A4
Chronic Viral Illness Service CRS
Montreal, Quebec, H4A 3J1
Centre hospitalier de l'Université Laval CRS
Québec, Quebec, G1V 4G2
Maple Leaf Research CRS
Toronto, Ontario, M5G 1K2
Toronto General Hospital CRS
Toronto, Ontario, M5G 2N2
Vancouver ID Research & Care Centre Society CRS
Vancouver, British Columbia, V6Z 2C7
South Africa5 sites
University of Cape Town Lung Institute (UCTLI) CRS
Cape Town, Western Cape, 7700
Durban International Clinical Research Site CRS
Durban, KwaZulu-Natal, 4052
Soweto ACTG CRS
Johannesburg, Gauteng, 1862
Wits Helen Joseph Hospital CRS (Wits HJH CRS)
Johannesburg, Gauteng, 2092
Famcru Crs
Tygerberg, Western Cape, 7505
Haiti2 sites
GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS
Port-au-Prince, HT-6110
Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS
Port-au-Prince, HT-6110
India2 sites
Chennai Antiviral Research and Treatment (CART) CRS
Chennai, Tamil Nadu, 600113
Byramjee Jeejeebhoy Medical College (BJMC) CRS
Pune, Maharashtra, 411001
Thailand2 sites
Thai Red Cross AIDS Research Centre (TRC-ARC) CRS
Bangkok, 10330
Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS
Chiang Mai, 50200
Puerto Rico1 site
Puerto Rico AIDS Clinical Trials Unit CRS*
San Juan, PR, 00935
Uganda1 site
Joint Clinical Research Centre (JCRC)/Kampala Clinical Research Site
Kampala
About this study
Official title: Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE
People with HIV are at risk for cardiovascular disease (CVD). This study evaluated the use of pitavastatin to reduce the risk of CVD in adults with HIV on antiretroviral therapy (ART).
The REPRIEVE trial consisted of two parallel identical protocols:
- REPRIEVE (A5332) was funded by the NHLBI, with additional infrastructure support provided by the NIAID, and was conducted in U.S and select international sites (approximately 120 sites in 11 countries).
- REPRIEVE (EU5332) was co-sponsored by NEAT ID and MGH, and was conducted at 13 sites in Spain.
Read the detailed description
There are few strategies to prevent CVD in people with HIV (PWH), even though they are at high risk for developing CVD. Statin medications are used to lower cholesterol and may be effective at reducing the risk of CVD in PWH. The purpose of this study was to evaluate the use of pitavastatin to reduce the risk of CVD in PWH on ART.
This study enrolled PWH who were on any ART regimen (ART was not provided by the study) for at least 6 months before study entry and were at low to moderate risk of CVD using the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guideline thresholds for recommended statin initiation.
Participants were randomly assigned to receive 4 mg of pitavastatin or placebo once a day for their entire study duration. Pitavastatin or placebo could be discontinued and clinically indicated statin therapy initiated at the discretion of the site investigator or the participant's care provider, with the intention of following the participant according to the intention-to-treat trial design. Study visits occurred at study entry and Months 1 and 4. Starting at Month 4, study visits occurred every 4 months for the rest of the study. Depending on when participants enrolled, they were in the study for a total of 4 to 8 years. Study visits included medical and medication history reviews, physical examinations, blood collections, assessments and questionnaires, urine collections (for some participants), and an electrocardiogram (ECG) (at study entry only).
Participants at US sites had the option of enrolling in a substudy (Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers: Mechanistic Substudy of REPRIEVE [A5333s]). The substudy evaluated the effect of pitavastatin on the progression of non-calcified coronary atherosclerotic plaque (NCP) and inflammatory biomarkers in PWH. Participants in the substudy attended study visits at study entry and Months 4 and 24. The visits included questionnaires and assessments, a blood collection, and a coronary computed tomography angiography (CCTA). The Mechanistic Substudy closed to accrual on February 6, 2018, when its accrual target of 800 participants had been reached. Sites that enrolled participants into the Mechanistic Substudy are indicated with asterisk (*) at the end of the institution names in the Contacts and Locations section.
Participants enrolled in REPRIEVE from select study sites, including international sites, through December, 2017, were included in the REPRIEVE Kidney Function Objectives Cohort to evaluate the effects of pitavastatin on parameters of kidney function in the setting of HIV. These objectives include evaluating high risk groups and mechanisms driving kidney function decline in the setting of HIV.
Women and men enrolled in REPRIEVE after February, 2016 were included in an observational cohort (REPRIEVE Women's Objectives Cohort) facilitating assessment of sex-specific mechanisms of CVD risk and risk reduction among PWH. This effort also included an evidence-based recruitment campaign to enhance women's participation in REPRIEVE.
In response to the SARS-CoV-2 pandemic, a supplemental objective was added in 2020. To better understand how COVID-19 affects PWH and if pitavastatin may reduce the risk of serious COVID-19 disease, we evaluated interrelated but independent key topics including epidemiology, host factors, and protective strategies. Starting from April 2020, COVID-19 assessment was completed at each study visit, and blood was collected for COVID-19 biomarkers.
The data and safety monitoring board (DSMB) recommended stopping the trial for efficacy at the second planned review on March 30, 2023, and concluded that no unexpected safety concerns had been reported. Following the DSMB action, participants were asked to return for the final study visit. All final visits were completed by August 21, 2023. We here present the results based on the final trial database, including the full follow-up out to closeout visits.
- Conditions
- HIV, Cardiovascular Diseases
- Being tested
- Pitavastatin, Placebo
- Keywords
- HIV, Cardiovascular Disease, Myocardial Infarction, Inflammation, Statin, Computerized Tomography, Cholesterol, COVID-19
- Medical subject headings
- Cardiovascular Diseases, Myocardial Infarction, Inflammation, COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PitavastatinDrug
One tablet (4 mg) taken once daily, orally with or without food
PlaceboDrug
One tablet taken once daily, orally with or without food
| Study group | Role | What they receive |
|---|---|---|
| Pitavastatin | Experimental | Participants received pitavastatin once a day for the entire time they were in study follow-up. Receives: Drug: Pitavastatin |
| Placebo | Placebo comparator | Participants received placebo for pitavastatin once a day for the entire time they were in study follow-up. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence Rate of Major Adverse Cardiovascular Event (MACE)
MACE is a composite of cardiovascular (CV) death, myocardial infarction, hospitalization for unstable angina, stroke, transient ischemic attack (TIA), peripheral arterial ischemia, coronary, carotid or peripheral arterial revascularization, or death from an undetermined cause. The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated via cause-specific relative hazard (i.e. hazard ratio) of prescribed pitavastatin compared to placebo from Cox proportional hazards models, stratified by screening CD4 count and sex. Non-CV deaths (without preceding event of interest) were treated as competing events and censored. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Secondary outcomes (34)
Incidence Rate of Cardiac Ischemia or Myocardial Infarction
Cardiac ischemia or myocardial infarction component of the primary composite MACE outcome. The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated via cause-specific relative hazard (i.e. hazard ratio) of prescribed pitavastatin compared to placebo from Cox proportional hazards models, stratified by screening CD4 count and sex. Deaths (without preceding event of interest) were treated as competing events and censored. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of Cerebrovascular Event (Stroke or TIA)
Cerebrovascular event (stroke or TIA) component of the primary composite MACE outcome. The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated via cause-specific relative hazard (i.e. hazard ratio) of prescribed pitavastatin compared to placebo from Cox proportional hazards models, stratified by screening CD4 count and sex. Deaths (without preceding event of interest) were treated as competing events and censored. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of Peripheral Arterial Ischemia
Peripheral arterial ischemia component of the primary composite MACE outcome. The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated via cause-specific relative hazard (i.e. hazard ratio) of prescribed pitavastatin compared to placebo from Cox proportional hazards models, stratified by screening CD4 count and sex. Deaths (without preceding event of interest) were treated as competing events and censored. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of Death From CV Causes
CV death component of the primary composite MACE outcome. The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated via cause-specific relative hazard (i.e. hazard ratio) of prescribed pitavastatin compared to placebo from Cox proportional hazards models, stratified by screening CD4 count and sex. Non-CV deaths and deaths from undetermined causes were treated as competing events and censored. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of Death From CV or Undetermined Causes
CV or undetermined death component of the primary composite MACE outcome. The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated via cause-specific relative hazard (i.e. hazard ratio) of prescribed pitavastatin compared to placebo from Cox proportional hazards models, stratified by screening CD4 count and sex. Non-CV deaths were treated as competing events and censored. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of Cardiac Catheterization or Revascularization
Cardiac cardiac catheterization or revascularization component of the primary composite MACE outcome. The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated via cause-specific relative hazard (i.e. hazard ratio) of prescribed pitavastatin compared to placebo from Cox proportional hazards models, stratified by screening CD4 count and sex. Deaths (without preceding event of interest) were treated as competing events and censored. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of Carotid or Cerebrovascular Revascularization
Carotid or cerebrovascular revascularization component of the primary composite MACE outcome. The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated via cause-specific relative hazard (i.e. hazard ratio) of prescribed pitavastatin compared to placebo from Cox proportional hazards models, stratified by screening CD4 count and sex. Deaths (without preceding event of interest) were treated as competing events and censored. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of Peripheral Arterial Revascularization
Peripheral arterial revascularization component of the primary composite MACE outcome. The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated via cause-specific relative hazard (i.e. hazard ratio) of prescribed pitavastatin compared to placebo from Cox proportional hazards models, stratified by screening CD4 count and sex. Deaths (without preceding event of interest) were treated as competing events and censored. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of MACE or Death
A composite outcome including MACE and death from any cause. The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated via relative hazard (i.e. hazard ratio) of prescribed pitavastatin compared to placebo from Cox proportional hazards models, stratified by screening CD4 count and sex. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of Death (All-cause)
Death from any cause. The incidence rates were estimated based on time to event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated via relative hazard (i.e. hazard ratio) of prescribed pitavastatin compared to placebo from Cox proportional hazards models, stratified by screening CD4 count and sex. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of Non-CV Clinical Diagnoses
A composite of non-CV clinical diagnoses including: non-AIDS-defining cancers (excluding basal cell and squamous cell carcinomas of the skin), AIDS-defining events (based on Centers for Disease Control and Prevention [CDC] 2014 classification), end-stage renal disease, and end-stage liver disease. The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated via cause-specific relative hazard (i.e. hazard ratio) of prescribed pitavastatin compared to placebo from Cox proportional hazards models, stratified by screening CD4 count and sex. Deaths (without preceding event of interest) were treated as competing events and censored. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of Non-AIDS-defining Cancer
Non-AIDS-defining cancer (excluding basal cell and squamous cell carcinomas of the skin) component of the composite non-CV clinical diagnoses outcome. The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated via cause-specific relative hazard (i.e. hazard ratio) of prescribed pitavastatin compared to placebo from Cox proportional hazards models, stratified by screening CD4 count and sex. Deaths (without preceding event of interest) were treated as competing events and censored. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of AIDS-defining Event
AIDS-defining event component of the composite non-CV clinical diagnoses outcome. Events were captured based on the Centers for Disease Control and Prevention [CDC] 2014 classification. The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated via cause-specific relative hazard (i.e. hazard ratio) of prescribed pitavastatin compared to placebo from Cox proportional hazards models, stratified by screening CD4 count and sex. Deaths (without preceding event of interest) were treated as competing events and censored. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of End-Stage Renal Disease
End-stage renal disease (defined as initiation of dialysis or renal transplantation) component of the composite non-CV clinical diagnoses outcome. The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated via cause-specific relative hazard (i.e. hazard ratio) of prescribed pitavastatin compared to placebo from Cox proportional hazards models, stratified by screening CD4 count and sex. Deaths (without preceding event of interest) were treated as competing events and censored. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of End-Stage Liver Disease
End-stage liver disease (defined as cirrhosis or hepatic decompensation requiring hospitalization) component of the composite non-CV clinical diagnoses outcome. The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated via cause-specific relative hazard (i.e. hazard ratio) of prescribed pitavastatin compared to placebo from Cox proportional hazards models, stratified by screening CD4 count and sex. Deaths (without preceding event of interest) were treated as competing events and censored. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of Non-fatal Serious Adverse Event
Safety analysis outcome measure of non-fatal serious adverse event was defined by International Conference on Harmonisation (ICH) criteria. Fatal events were excluded as deaths were a secondary efficacy outcome (see outcome measure: incidence rate of death (all-cause)). The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated using incidence rate ratios from Poisson regression models (prescribed pitavastatin compared to placebo), adjusted for screening CD4 and sex. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of Diabetes
Safety analysis outcome measure of diabetes was defined as new diagnosis of diabetes with initiation of anti-diabetic agent. The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated using incidence rate ratios from Poisson regression models (prescribed pitavastatin compared to placebo), adjusted for screening CD4 and sex. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of Myalgia, Muscle Weakness or Myopathy
Safety analysis outcome measure of myalgia, muscle weakness or myopathy which were grade 3 or higher or treatment-limiting. Grade 3 or higher includes grade 3 and 4 events, where grade 3 refers to severe and grade 4 to life-threatening according to DAIDS AE Grading Table (version 2.1). The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated using incidence rate ratios from Poisson regression models (prescribed pitavastatin compared to placebo), adjusted for screening CD4 and sex. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of Rhabdomyolysis
Safety analysis outcome measure of rhabdomyolysis which was grade 3 or higher or treatment-limiting. Grade 3 or higher includes grade 3 and 4 events, where grade 3 refers to severe and grade 4 to life-threatening, according to DAIDS AE Grading Table (version 2.1). The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated using incidence rate ratios from Poisson regression models (prescribed pitavastatin compared to placebo). Due to small number of events, there was no adjustment for screening CD4 and sex. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of Grade 3 or Higher ALT
Safety analysis outcome measure of Grade 3 or higher alanine transaminase (ALT). Grade 3 or higher includes grade 3 and 4 events, where grade 3 refers to severe and grade 4 to life-threatening, according to DAIDS AE Grading Table (version 2.1). The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated using incidence rate ratios from Poisson regression models (prescribed pitavastatin compared to placebo). Due to small number of events, there was no adjustment for screening CD4 and sex. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Incidence Rate of Adverse Event (AE)
Safety analysis outcome measure of any AE. AE collection included events of grade ≥3, those that were serious (defined by International Conference on Harmonisation (ICH) criteria) or treatment-limiting, and targeted diagnosis of diabetes. Grade ≥3 includes events that were grade 3 (serious) or grade 4 (life-threatening) per DAIDS AE Grading Table (version 2.1). Fatal events were excluded as deaths were a secondary efficacy outcome (see outcome measure: incidence rate of death (all-cause)). The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated using incidence rate ratios from Poisson regression models (prescribed pitavastatin compared to placebo), adjusted for screening CD4 and sex. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).
Fasting Low-density Lipoprotein Cholesterol (LDL-C)
LDL-C level was derived as LDL-C calculated according to the Friedewald formula at triglycerides ≤400 mg/dL, and direct LDL-C at triglycerides >400 to <500 mg/dL. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: At entry and months 12, 24, 36, 48, 60, 72, 84. Participants' follow-up time on study varied, depending on their time of enrollment.
Fasting Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
Non-HDL cholesterol levels were calculated as total cholesterol minus HDL cholesterol. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: At entry and months 12, 24, 36, 48, 60, 72, 84. Participants' follow-up time on study varied, depending on their time of enrollment.
Incidence Rate of Serious COVID-19
Serious COVID-19 was defined as COVID-19 that resulted in hospitalization or death or was life-threatening as per the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Guideline E2A definition. The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated using incidence rate ratios from Poisson regression models (prescribed pitavastatin compared to placebo), adjusted for GBD region to account for regional differences. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: From January 1, 2020 through end of study; the median follow-up time was 3.3 years.
Incidence Rate of COVID-19
COVID-19 was defined as COVID-19 clinical diagnosis or positive test result (SARS-CoV-2 PCR or rapid antigen tests). The incidence rates were estimated based on time to the first event using Poisson distribution, with follow-up time censored at last contact. The treatment effect was estimated using incidence rate ratios (prescribed pitavastatin compared to placebo) from Poisson regression models, adjusted for GBD region to account for regional differences. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: From January 1, 2020 through end of study; the median follow-up time was 3.3 years.
For Mechanistic Substudy: Change in Non-Calcified Plaque (NCP) Volume From Baseline to Year 2
NCP was defined as plaque voxels with attenuation of <350. Change in NCP is expressed as absolute change from baseline (calculated as NCP volume at 2 years minus NCP volume at entry), based on quantitative read of the CT scan, whenever available. Participants without a quantitative read and no evidence of NCP based on the corresponding qualitative read were assigned a value of zero for the change. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: Entry and Year 2.
For Mechanistic Substudy: Number of Participants With Progression of NCP From Baseline to Year 2
Progression at Year 2 was defined as any progression/increase in NCP volume in participants with evidence of NCP at entry, or incident NCP in participants without evidence of NCP at entry. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: Entry and year 2.
For Mechanistic Substudy: Change in Total Plaque Volume From Baseline to Year 2
Total plaque includes all plaque voxels (noncalcified + calcified). Change in total plaque volume is expressed as absolute change from baseline (calculated as volume at 2 years minus volume at entry). Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: Entry and year 2.
For Mechanistic Substudy: LpPLA2 Level
Level of inflammatory biomarker lipoprotein-associated phospholipase A2 (LpPLA2). Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: Entry and month 24.
For Mechanistic Substudy: Change in LpPLA2 From Baseline
Change in inflammatory biomarker LpPLA2 from baseline calculated as value at month 24 minus value at entry. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: Entry and month 24.
For Mechanistic Substudy: HsCRP Level
Level of inflammatory marker high-sensitivity C-reactive protein (HsCRP). Censored values below or above the assay limit were imputed. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: Entry and month 24.
For Mechanistic Substudy: Change in HsCRP From Baseline
Change in inflammatory biomarker hsCRP from baseline calculated as value at month 24 minus value at entry. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: Entry and month 24.
For Mechanistic Substudy: Soluble CD163 Level
Level of immune biomarker soluble CD163. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: Entry and month 24.
For Mechanistic Substudy: Change in Soluble CD163 From Baseline
Change in immune biomarker soluble CD163 from baseline calculated as value at month 24 minus value at entry. Treatment discontinuation was ignored, including the initiation of statin therapy as part of clinical care (intention to treat policy).
Measured: Entry and month 24.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jan 2015 (estimated)
- Study start26 Mar 2015
- Primary completion21 Aug 2023
- Study completion21 Aug 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (59)Papers the sponsor has linked to this study.
- Other trials for HIVStudies of the same condition, open and under way.
- More trials run by National Institute of Allergy and Infectious Diseases (NIAID)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 7,769 participants (actual)
Sponsor and investigators
- Sponsor type
- US National Institutes of Health
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI), Kowa Pharmaceuticals America, Inc., Gilead Sciences, Massachusetts General Hospital, NEAT ID Foundation
- Responsible party
- Sponsor
- Investigators
- Steven Grinspoon, MD, Study chair, Harvard Medical School (HMS and HSDM)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02344290
- Sponsor's protocol ID
- A5332
- Other IDs
- 11960, 1U01HL123339-01, 1U01HL123336-01, EU5332
- Acronym
- REPRIEVE
- Status last verified
- Sep 2025
- First submitted
- 16 Jan 2015
- Last updated
- 4 Sep 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PWF. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2935-2959. doi: 10.1016/j.jacc.2013.11.005. Epub 2013 Nov 12. No abstract available.
PubMed 24239921Zanni MV, Fitch K, Rivard C, Sanchez L, Douglas PS, Grinspoon S, Smeaton L, Currier JS, Looby SE. Follow YOUR Heart: development of an evidence-based campaign empowering older women with HIV to participate in a large-scale cardiovascular disease prevention trial. HIV Clin Trials. 2017 Mar;18(2):83-91. doi: 10.1080/15284336.2017.1297551.
PubMed 28277924Grinspoon SK, Fitch KV, Overton ET, Fichtenbaum CJ, Zanni MV, Aberg JA, Malvestutto C, Lu MT, Currier JS, Sponseller CA, Waclawiw M, Alston-Smith B, Cooper-Arnold K, Klingman KL, Desvigne-Nickens P, Hoffmann U, Ribaudo HJ, Douglas PS; REPRIEVE Investigators. Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). Am Heart J. 2019 Jun;212:23-35. doi: 10.1016/j.ahj.2018.12.016. Epub 2019 Mar 4.
PubMed 30928825Hoffmann U, Lu MT, Olalere D, Adami EC, Osborne MT, Ivanov A, Aluru JS, Lee S, Arifovic N, Overton ET, Fichtenbaum CJ, Aberg JA, Alston-Smith B, Klingman KL, Waclawiw M, Burdo TH, Williams KC, Zanni MV, Desvigne-Nickens P, Cooper-Arnold K, Fitch KV, Ribaudo H, Douglas PS, Grinspoon SK; REPRIEVE Investigators. Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers. Am Heart J. 2019 Jun;212:1-12. doi: 10.1016/j.ahj.2019.02.011. Epub 2019 Mar 4.
PubMed 30928823Grinspoon SK, Douglas PS, Hoffmann U, Ribaudo HJ. Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators. J Infect Dis. 2020 Jul 9;222(Suppl 1):S1-S7. doi: 10.1093/infdis/jiaa098.
PubMed 32645161Fitch KV, Kileel EM, Looby SE, Zanni MV, Sanchez LR, Fichtenbaum CJ, Overton ET, Malvestutto C, Aberg JA, Klingman KL, Alston-Smith B, Lavelle J, Rancourt A, Badal-Faesen S, Cardoso SW, Avihingsanon A, Patil S, Sponseller CA, Melbourne K, Ribaudo HJ, Cooper-Arnold K, Desvigne-Nickens P, Hoffmann U, Douglas PS, Grinspoon SK; REPRIEVE Investigators. Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination. HIV Res Clin Pract. 2020 Feb;21(1):11-23. doi: 10.1080/25787489.2020.1733794. Epub 2020 Mar 11.
PubMed 32160827Overton ET, Kantor A, Fitch KV, Muntner P, Supparatpinyo K, Mosepele M, Mohapi L, Cardoso SW, Patil S, de Lacerda MVG, McComsey G, Aberg JA, Douglas PS, Grinspoon SK, Ribaudo H, Wyatt CM. An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus. J Infect Dis. 2020 Jul 9;222(Suppl 1):S41-S51. doi: 10.1093/infdis/jiaa222.
PubMed 32645164Fichtenbaum CJ, Ribaudo HJ, Leon-Cruz J, Overton ET, Zanni MV, Malvestutto CD, Aberg JA, Kileel EM, Fitch KV, Van Schalkwyk M, Kumarasamy N, Martinez E, Santos BR, Joseph Y, Lo J, Siminski S, Melbourne K, Sponseller CA, Desvigne-Nickens P, Bloomfield GS, Currier JS, Hoffmann U, Douglas PS, Grinspoon SK; REPRIEVE Investigators. Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. J Infect Dis. 2020 Jul 9;222(Suppl 1):S8-S19. doi: 10.1093/infdis/jiaa259.
PubMed 32645162Smeaton LM, Kileel EM, Grinsztejn B, Gardner EM, Starr K, Murry ML, Desvigne-Nickens P, Alston-Smith B, Waclawiw MA, Cooper-Arnold K, Madruga JV, Sangle S, Fitch KV, Zanni MV, Douglas PS, Ribaudo HJ, Grinspoon SK, Klingman KL. Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum. J Infect Dis. 2020 Jul 9;222(Suppl 1):S31-S40. doi: 10.1093/infdis/jiaa213.
PubMed 32645160Zanni MV, Currier JS, Kantor A, Smeaton L, Rivard C, Taron J, Burdo TH, Badal-Faesen S, Lalloo UG, Pinto JA, Samaneka W, Valencia J, Klingman K, Allston-Smith B, Cooper-Arnold K, Desvigne-Nickens P, Lu MT, Fitch KV, Hoffman U, Grinspoon SK, Douglas PS, Looby SE. Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial. J Infect Dis. 2020 Jul 9;222(Suppl 1):S20-S30. doi: 10.1093/infdis/jiaa214.
PubMed 32645159Neilan TG, Nguyen KL, Zaha VG, Chew KW, Morrison L, Ntusi NAB, Toribio M, Awadalla M, Drobni ZD, Nelson MD, Burdo TH, Van Schalkwyk M, Sax PE, Skiest DJ, Tashima K, Landovitz RJ, Daar E, Wurcel AG, Robbins GK, Bolan RK, Fitch KV, Currier JS, Bloomfield GS, Desvigne-Nickens P, Douglas PS, Hoffmann U, Grinspoon SK, Ribaudo H, Dawson R, Goetz MB, Jain MK, Warner A, Szczepaniak LS, Zanni MV. Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial. J Infect Dis. 2020 Jul 9;222(Suppl 1):S63-S69. doi: 10.1093/infdis/jiaa245.
PubMed 32645158Douglas PS, Umbleja T, Bloomfield GS, Fichtenbaum CJ, Zanni MV, Overton ET, Fitch KV, Kileel EM, Aberg JA, Currier J, Sponseller CA, Melbourne K, Avihingsanon A, Bustorff F, Estrada V, Ruxrungtham K, Saumoy M, Navar AM, Hoffmann U, Ribaudo HJ, Grinspoon S. Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. Clin Infect Dis. 2021 Dec 6;73(11):2009-2022. doi: 10.1093/cid/ciab552.
PubMed 34134131Hoffmann U, Lu MT, Foldyna B, Zanni MV, Karady J, Taron J, Zhai BK, Burdo T, Fitch KV, Kileel EM, Williams K, Fichtenbaum CJ, Overton ET, Malvestutto C, Aberg J, Currier J, Sponseller CA, Melbourne K, Floris-Moore M, Van Dam C, Keefer MC, Koletar SL, Douglas PS, Ribaudo H, Mayrhofer T, Grinspoon SK; REPRIEVE trial. Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention. JAMA Netw Open. 2021 Jun 1;4(6):e2114923. doi: 10.1001/jamanetworkopen.2021.14923.
PubMed 34185068Kileel EM, Lo J, Malvestutto C, Fitch KV, Zanni MV, Fichtenbaum CJ, Overton ET, Okeke NL, Kumar P, Joao E, Aberg JA, Martinez E, Currier JS, Douglas PS, Ribaudo HJ, Grinspoon SK. Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus. Open Forum Infect Dis. 2021 Nov 20;8(12):ofab537. doi: 10.1093/ofid/ofab537. eCollection 2021 Dec.
PubMed 34888395Fulda ES, Fitch KV, Overton ET, Zanni MV, Aberg JA, Currier JS, Lu MT, Malvestutto C, Fichtenbaum CJ, Martinez E, Umbleja T, Douglas PS, Ribaudo HJ, Grinspoon SK. COVID-19 Vaccination Rates in a Global HIV Cohort. J Infect Dis. 2022 Feb 15;225(4):603-607. doi: 10.1093/infdis/jiab575.
PubMed 34794178